Abstract: A biocompatible polymer to which a plurality of clot-modulating peptides (CMPs) are bound. The polymer comprises repeating units of hydrophilic monomers and display monomers to which the CMPs are bound. For example, the CMPs can be fibrin binding peptides (FBPs) that enhance clot formation by cross-linking that occurs within and between fibers by the plurality of fibrin-binding peptides during fibrin polymerization. The polymers of the invention can be used to modulate clotting in a variety of ways via multivalent display of fibrin-binding peptides and other clot-binding and clot-modulating moieties on polymer or co-polymer backbones. In addition to clot-modulating moieties, imaging agents and therapeutic agents can be conjugated to the polymers to facilitate imaging of blood flow and thrombosis, and for treatment of clotting-related disorders.
Type:
Application
Filed:
June 27, 2014
Publication date:
September 15, 2016
Applicant:
UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Inventors:
Suzie H. PUN, Leslie CHAN, Nathan J. WHITE
Abstract: Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. Also provided are methods of reducing cell proliferation in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof.
Abstract: Various embodiments of the present disclosure pertain to methods of optimizing a treatment efficacy of a biological system by tuning a property of the biological system through the addition of an optimizing agent to the biological system. The tuning can include: (a) determining a property parameter of the biological system; (b) selecting an optimizing agent to be added to the biological system based on the determined property parameter; and (c) adding the optimizing agent to the biological system. The optimizing agent can include a kosmotropic material. The biological system can include a tissue, such as a tumor. The methods of the present disclosure can be utilized to enhance the efficacy of various treatments, such as the heat treatment of a biological system exposed to a radiofrequency field. The methods of the present disclosure can also include a step of treating the biological system.
Type:
Application
Filed:
March 10, 2016
Publication date:
September 15, 2016
Applicants:
Baylor College of Medicine, William Marsh Rice University
Inventors:
Nadia C. Lara, Andrew R. Barron, Stuart Corr, Steven Curley
Abstract: Compositions and methods of utilizing the same are provided for treating bacterial infections. The compositions comprise acidified nitrite in combination with an iron chelator and an antibiotic. The compositions of the present invention are effective at treating bacterial infections with minimal to no side effects. Surprisingly, the combination of these three agents has a synergistic effect, which advantageously permits a lower dose of one or more of the active agents (e.g., the antibiotic).
Abstract: The present invention provides compositions and methods for facilitating cleansing of the gastrointestinal tract of a patient prior to a diagnostic, surgical or therapeutic procedure. The composition can improve patient compliance, and thus, efficacy of the preparation. Specifically, the composition of the invention is palatable for the patient to consume. For example, for a patient preparing to undergo colonoscopy, the present methods make the bowel preparation liquid taste significantly less salty.
Abstract: The present invention relates to compositions for weight management comprising: a) a microbiome modifying component; b) a satiety modifying component; and c) a metabolic modifying component. The composition may also be used for the treatment of obesity, elevated cholesterol, diabetes, hypertension or heart disease.
Abstract: An antibacterial composition comprising arginine bicarbonate, zinc carbonate, preferably arginine bicarbonate and zinc carbonate (ABZC), in combination, plus one or more physiologically acceptable excipients, administered for the modification of cutaneous microfloras, generally to inhibit the growth of pathogenic Staphylococcus aureus bacteria by promoting the growth of non-pathogenic Staphylococcus epidermidis bacteria.
Abstract: The technology relates in part to compositions and methods for inducing an immune response against the Preferentially Expressed Antigen of Melanoma (PRAME). Provided are methods for treating hyperproliferative diseases by inducing an immune response against PRAME antigen; the immune response may be induced by specifically targeting PRAME-expressing cells using T cell receptors directed against PRAME.
Type:
Application
Filed:
March 9, 2016
Publication date:
September 15, 2016
Inventors:
Mirjam H.M. HEEMSKERK, J.H. Frederik FALKENBURG
Abstract: Cell-based therapies show considerable potential as an immunomodulatory strategy for a variety of lung diseases, including chronic obstructive pulmonary disease (COPD), asthma, bronchiolitis, acute lung injury, lung allograft rejection (acute or chronic), pulmonary fibrosis. Described herein is the development of red blood cell membrane-derived microparticles (RBC MPs), which are depleted of hemoglobin (Hb) and express phosphatidylserine on their surface, for the treatment of lung disease. Administration of RBC MPs to the lung via inhalation promotes the production of immunoregulatory cytokines (such as IL-10), and reduces inflammation and injury in the lung.
Type:
Application
Filed:
November 6, 2014
Publication date:
September 15, 2016
Applicant:
University of Pittsburgh - Of the Commonwealth System of Higher Education
Inventors:
Janet S. Lee, Timothy E. Corcoran, Valerian Kagan
Abstract: Preactivated and disaggregated shape-changed platelets, fixed shape-changed platelets, and a pharmaceutical composition thereof are used for treating acute and emergent inflammatory disease in a dosage of 1×106 to 1×108. SC-PLT is a disaggregated and activated platelet, the secretome from platelet activation has been deprived after SC-PLT preparation but their membrane still preserve cell adhesion molecular and integrin glycoprotein (eg. P-selectin, GP1a, and GPIIb etc.). Therefore, SC-PLTs can trap stromal vascularity inflammatory cells from inflammated and damaged place, and the stromal vascularity inflammatory cells are eliminated through the circulatory system to alleviate inflammation. The fixed shape-changed platelets are able to alleviate inflammation and sustainable for longer storage duration.
Abstract: The present invention concerns methods for enhancing the engraftment and improving transplantation outcome of hematopoietic stem and progenitor cells by exposure of the cells to ligands of the TNF superfamily prior to transplantation. The invention also provides populations of hematopoietic stem and progenitor cells that were activated according to the method of the invention, for use in transplantation.
Abstract: Disclosed herein are methods and compositions for stimulating angiogenesis, using cells descended from marrow adherent stromal cells that have been transfected with sequences encoding a Notch intracellular domain. Applications of these methods and compositions include treatment of ischemic disorders such as stroke.
Abstract: Compositions and methods for delivering a siRNA, dsRNA, or miRNA polynucleotide into a target cell comprising contacting the target cell with a mesenchymal stem cell, which mesenchymal stem cell comprises an exogenous DNA sequence expressing the siRNA or dsRNA polynucleotide, thereby delivering the siRNA, dsRNA, or miRNA polynucleotide to the target cell through a cellular protrusion or a microvesicle.
Type:
Application
Filed:
May 23, 2016
Publication date:
September 15, 2016
Inventors:
Jan A. Nolta, Scott Olson, Louisa Wirthlin
Abstract: The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration of symptoms for gastro-esophageal pathologies like gastro-esophageal reflux.
Type:
Application
Filed:
March 11, 2016
Publication date:
September 15, 2016
Applicant:
University of Pittsburgh - Of the Commonwealth System of Higher Education
Inventors:
Michael B. Chancellor, Jay Pasricha, Ronald Jankowski, Ryan Pruchnic
Abstract: Disclosed are methods, compositions of matter, and cells, useful for the treatment of autism, social integrative disorders, and various cognitive abnormalities. The invention discloses, inter alia, means of inducing angiogenesis and immune modulation either in sequence or parallel in order to substantially ameliorate or reverse the progression of autism. The use of stem cells, and cells naturally possessing or endowed with angiogenic and anti-inflammatory activity are disclosed for autism either alone or in combination with various therapeutic interventions.
Abstract: The presently disclosed subject matter provides populations of stem cells that are purified from bone marrow, peripheral blood, and/or other sources. Also provided are methods of using the stem cells for treating tissue and/or organ damage in a subject.
Type:
Application
Filed:
September 3, 2015
Publication date:
September 15, 2016
Inventors:
MARIUSZ RATAJCZAK, MAGDALENA KUCIA, JANINA RATAJCZAK, DENIS RODGERSON, GEORGE SMITH, RONALD ALLEN, WAYNE MARASCO, ROBERTO BOLLI
Abstract: A dietary supplement composition and associated method has its composition formulated in a therapeutic amount to treat and alleviate symptoms of joint pain in a person having joint pain. The composition includes astaxanthin, low molecular weight hyaluronic acid or sodium hyaluronate (hyaluronan) having a molecular weight of 0.5 to 300 kilodaltons (kDa), and a phospholipid rich egg roe extract having phospholipid bound EPA and DHA admixed with seed and/or fish oil having an ALA to LA ratio of 1:1 to 6:1 and in an oral dosage form.
Type:
Application
Filed:
May 24, 2016
Publication date:
September 15, 2016
Inventors:
John A. Minatelli, W. Stephen Hill, Rudi E. Moerck
Abstract: The present invention relates to a method for fermenting fish skin by using Aspergillus. Also provided is a use of the fermentation liquid obtained by fermenting fish skin with Aspergillus obtained from the method in inhibiting the activity of tyrosinase, inhibiting the activity of angiotensin-converting enzyme and/or improving the survival of fibroblasts.
Abstract: A method of determining tolerance to an agent in a healthy subject is disclosed. The method comprises: (a) determining a signature of a microbiome in a sample of the healthy subject who has been subjected to the agent or condition; and (b) comparing the signature of the microbiome of the healthy subject to at least one reference signature of a pathological microbiome, wherein when the signature of the microbiome of the healthy subject is statistically significantly similar to the reference signature of the pathological microbiome, it is indicative that the healthy subject is intolerant to the agent.
Abstract: A phytochemical anti-pathogen/anti-cancer composition is provided that includes an extract of mangosteen; an extract of defatted soybean; an extract of gotu kola; and optionally an extract of black sesame, where an amount of the extract of black sesame is controlled relative to an amount of the extract of gotu kola, or an amount of a combination of the extract of rriangosteen, the extract of defatted soybean, and the extract of gotu kola, in order to preferentially support antipathogen/anti-cancer immunomodulatoty effects. A phytochemical anti-autoimmune disorder composition containing the same four ingredients, where an amount of the extract of gotu kola is controlled relative to the amounts of the other extracts is also provided. The two compositions can support or provide antipode immunomodulatory effects relative to each other.
Abstract: A method of preparing tea comprising steps (a) selecting raw materials, wherein the raw materials include organic cumin seeds and organic funnel seeds; (b) washing the raw materials thoroughly; (c) sterilization of the raw materials via air-drying; (d) mixing a predetermined amount of organic funnel seeds and a predetermined amount of organic cumin seeds into a tea bags, wherein the tea bag is 1.5 g; (e) boiling 8 ounces of water, wherein the tea bag is added to the boiling water for 2 to 3 minutes; and (f) serving the tea to a baby at room temperature wherein the tea is intended for babies to reduce colic, gas, constipation, and acid reflux.
Abstract: The present invention relates to a composition comprising the extract of combined herbs consisting of heat processed ginseng, houttuyniae herba, perilla leaf and tea leaf or the processed extract thereof as active ingredients for preventing and treating hair baldness and stimulating activity of hair growth. The inventive combined extract showed more potent hair-growth promoting activity and synergistic effect than the precedent invention(s), for example, a fermented extract of Houttuyniae Herba, Perilla leaf and Tea leaf disclosed in Korea Patent Publication No, 10-2014-0114492 (A1), through various animal model experiments such as the growth rate test using by C57BL/6 mouse, the proliferating effect on the growth of HFDPC etc and additionally, more favorable advantage than the precedent invention(s), for example, the easiness in controlling the prescribed dosage by dint of the final form of the inventive extract, i.e.
Type:
Application
Filed:
August 19, 2015
Publication date:
September 15, 2016
Inventors:
Bok Deuk KIM, Sung Hyang KIM, Yang Beom LEE, Man Ki PARK, Yong Jae LEE
Abstract: A repressive sweetener composition comprising at least two sugar alcohols, monk fruit, a rheology modifier, and tagatose wherein the repressive sweetener composition has a glycemic index that is less than a sum of the glycemic index of each component of the repressive sweetener composition. A sweetener composition prepared by: (i) dry blending in a fluidized bed a rheology modifier, tagatose, stevia extract, xanthan gum, a flavor blend, erythritol, and a second sugar alcohol to form a first mixture; (ii) spray depositing water onto the first mixture to generate a wet mixture; and (iii) removing excess moisture from the wet mixture to generate granules.
Abstract: The present invention provides a nutraceutical composition, a process for the preparation of the nutraceutical composition useful for amelioration of peri- and post-menopausal symptoms in women. The nutraceutical composition is stable, directly compressible, water soluble, free flowing form having particle size not more than 2.0 ?m comprising extract of Trigonella foenum-graecum, at least one bioavailable form of magnesium and vitamin E. The present invention also provides a method of treating ameliorating, treating and/or preventing peri- and post-menopausal discomforts in a subject suffering from peri- or post-menopausal symptoms comprising administering to the subject a therapeutically effective amount of the nutraceutical composition.
Abstract: The invention provides a composition for treating a microbial disease in a bee. The composition comprises camphor oil and a volatile solvent. The invention also provides a method for treating a microbial disease in a bee comprising administrating the bee with a camphor oil solution, wherein the camphor oil solution comprises camphor oil and a volatile solvent, and the volatile solvent is able to dissolve the camphor oil.
Abstract: A topically administrable pain relief formulation comprises a Kunzea ambigua extract or one or more components or derivatives thereof; Menthol; Capsaicin; and a Hypericum perforatum extract or one or more components or derivatives thereof. The formulation may further comprise methyl salicylate, black pepper and/or an anti-inflammatory agent. The formulation may be used to treat or prevent pain such as arthritis neck pain, shoulder pain, back pain, preoperative and/or postoperative pain and pain associated with minor or traumatic injuries or other diseases or conditions.
Abstract: The present invention relates to a composition containing a paprika extract as an active ingredient, and more particularly to a pharmaceutical composition or health functional food for preventing or treating inflammatory, allergic or asthma disease, which contains a paprika extract. Particularly, paprika is a natural food which is readily available to anyone, and thus does not cause adverse effects even when it is taken for a long period of time.
Type:
Application
Filed:
February 24, 2016
Publication date:
September 15, 2016
Inventors:
Sang-Kyung LEE, Young-Jin YOU, Hyo-Sung CHOI, Min-Young PARK
Abstract: A method of producing a substance with antimicrobial, antiviral, and immunostimulatory activities, particularly towards dendritic cells is proposed, provides for using the chopped potato sprouts as plant raw materials are extracted with water, then the aqueous extract is centrifuged, a salt agent is added, and the obtained saline solution is then concentrated using ultrafiltration through a 300-kD filter, then the solution is frozen for 24 hours, thawed, and filtered, and the pellet thus obtained is removed, and the raw peptidoglycan is precipitated from the solution by using an acidic salt agent and is further re-solubilized with alkali, then the alkaline solution is dialyzed against distilled water on a 12 kD filter, and the peptidoglycan having a molecular weight of 500 kD to 17000 kD is purified from the resulting solution using gel permeation chromatography.
Type:
Application
Filed:
May 20, 2016
Publication date:
September 15, 2016
Inventors:
Ravshan I. ATAULLAKHANOV, Aleksey V. PICHUGIN, Tatyana M. MELNIKOVA, Rakhim M. KHAITOV
Abstract: The present invention relates to a composition comprising curcuminoid with green tea polyphenol or with a combination of glycine, proline and hydroxyproline for use in preventing or treating osteoarthritis. It also relates to a method of preventing or treating osteoarthritis in mammals, the method comprising administering to said mammal a composition which comprises curcuminoid with green tea polyphenol or with a combination of glycine, proline and hydroxyproline.
Type:
Application
Filed:
May 14, 2014
Publication date:
September 15, 2016
Applicant:
MARS, INCORPORATED
Inventors:
SAMUEL SERISIER, FANNY COMBLAIN, YVES HENROTIN
Abstract: An extract derived from sugar cane having GI or burn rate reducing characteristics wherein the extract comprises a mixture of one or more polyphenols, one or more carbohydrates, one or more minerals and one or more organic acids.
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating diabetes or dementia, comprising centipede grass (Eremochloa ophiuroides) extracts as an active ingredient. It has been identified from animal tests that the centipede grass extracts, fractions thereof, and active fractions separated from the said fractions effectively regulate blood glucose levels, and inhibit the activity of amyloid-?(A?) which is involved in the formation of amyloid plaques that might cause dementia. Thus, the extracts, the fractions thereof, and the active fractions separated from the said fractions can be effectively used in a composition for preventing and treating diabetes or dementia, in a functional food for preventing or improving diabetes or dementia, and in a pharmaceutical composition or health food for blood glucose regulation.
Type:
Application
Filed:
May 27, 2016
Publication date:
September 15, 2016
Applicant:
Korea Atomic Energy Research Institute
Inventors:
Byung Yeoup CHUNG, Sungbeom LEE, Hyoungwoo BAI, Seung Sik LEE
Abstract: A softgel of NLKJ for the treatment of prostate diseases, comprising 0.05-1.0 g of NLKJ and 0.05-1.5 mg of an antioxidant, said NLKJ having the following physicochemical parameter: acid value<0.56, iodine value 95.0-107.00, saponification value 185.00-195.00, specific gravity 0.914-0.918 (20° C.), and refractive index 1.470-1.475 (20° C.). The inhibition of the softgel of NLKJ on the growth of prostate cancer in combination with the injection of Lupron is stronger than that of each of them used alone.
Abstract: Methods and compositions for synchronizing the time of insemination in swine are described. More particularly, methods are described for synchronizing the time of insemination by administration of a composition comprising a hormone, wherein the swine is inseminated only one time after administration of the hormone, and wherein there is no heat detection.
Abstract: The present invention is directed to a method of treating a patient suffering from the metabolic syndrome and/or related disorders including obesity, Type 2 diabetes, pre-diabetes, hypertension, dyslipidemia, insulin resistance, endothelial dysfunction, pro-inflammatory state, and pro-coagulative state, and comprising the steps of (a) providing to the patient a dietary regimen that decreases overactive CNS noradrenergic tone; followed by (b) providing to the patient a dietary regimen that increases dopaminergic tone while maintaining the above decreased overactive CNS noradrenergic tone. The present invention is also directed to food products useful in implementing the dietary regimens.
Abstract: A method of selecting a semaphorin for treating cancer in a subject is disclosed. The method comprises determining an expression of a semaphorin receptor on tumor cells of a tumor sample of the subject wherein an amount of the semaphorin receptor is indicative of the semaphorin suitable for treating the cancer in the subject. Kits for treating cancer and pharmaceutical compositions comprising semaphorins are also disclosed.
Type:
Application
Filed:
September 8, 2015
Publication date:
September 15, 2016
Inventors:
Gera NEUFELD, Boaz Kigel, Ofra Kessler, Asya Varshavsky
Abstract: The methods and assays described herein relate to the diagnosis, prognosis, and treatment of subjects with emphysema, COPD, and/or cigarette-induced lung damage. In some embodiments, the methods and assays relate to subjects with a decreased level of NLRX1 expression. In some embodiments, the methods and assays relate to the administration of an agonist of NLRX1 and/or an inhibitor of MAVS.
Type:
Application
Filed:
March 9, 2016
Publication date:
September 15, 2016
Applicants:
BROWN UNIVERSITY, YALE UNIVERSITY
Inventors:
Jack A. Elias, Chun Geun Lee, Min-Jong Kang
Abstract: Methods of treating a condition in a subject resulting from abnormally high VEGF signaling through membrane-bound receptors. Such a method can include increasing expression of Raver2 in affected cells of the subject to increase production of soluble VEGF receptors. In some aspects, increasing expression of Raver2 decreases production of membrane-bound VEGF receptors.
Abstract: The present invention relates to binding proteins specific for VEGF-A, in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits VEGF-Axxx binding to VEGFR-2. Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration.
Type:
Application
Filed:
February 4, 2016
Publication date:
September 15, 2016
Inventors:
Hans Kaspar BINZ, Patrik FORRER, Michael Tobias STUMPP
Abstract: Cells transfected with DNA sequences encoding for a PreImplantation Factor (PIF) or a PIF and one or more fusion tag(s) are disclosed. Also disclosed are DNA sequences encoding for synthetic PIFs, a PIF fusion peptide made of a PIF and one or more fusion tags, methods of treatment using the transfected cells that express a PIF, an R-I-K-P peptide, compositions containing the R-I-K-P peptide, and methods of identifying a compound that binds to an active site of an WX1WX2X3X4REWFX5X6X7W receptor, wherein each X can be any amino acid.
Type:
Application
Filed:
October 22, 2014
Publication date:
September 15, 2016
Inventors:
Eytan R. BARNEA, Soren Bohos HAYRABEDYAN
Abstract: The described invention provides pharmaceutical compositions, systems and methods for treating a non-small cell lung cancer (NSCLC) solid tumor comprising a population of tumor cells. The method includes administering a pharmaceutical composition comprising a therapeutic amount of a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier, wherein therapeutic amount of the polypeptide is effective to inhibit a kinase activity in the population of tumor cells and to reduce cancer cell proliferation, to reduce tumor size, to reduce tumor burden, to induce tumor cell death, to overcome tumor chemoresistance, to enhance tumor chemosensitivity, or a combination thereof.
Type:
Application
Filed:
March 10, 2016
Publication date:
September 15, 2016
Inventors:
Cynthia Lander, Colleen Brophy, Caryn Peterson, Andrew Luber
Abstract: The present invention relates to a composition which comprises the following myelin basic protein peptides: MBP 30-44; MBP 83-99; MBP 131-145; and MBP 140-154. The composition may be used to treat a disease, in particular multiple sclerosis and/or optical neuritis and the invention also relates to such uses and methods.
Abstract: Provided herein are methods for treating a neurodegenerative disease or disorder, or stroke using a combination of one or more RXR agonist and/or one or more Nurr1 agonist and one or more trophic factor, or pharmaceutically acceptable salts thereof. Additionally, compositions comprising of one or more RXR agonist and/or one or more Nurr1 agonist and one or more trophic factor, or pharmaceutically acceptable salts thereof for treatment of a neurodegenerative disease or disorder, or stroke are provided.
Abstract: Described herein are modified fibroblast growth factors (FGFs), pharmaceutical compositions, ophthalmic formulations, and medicaments that include such modified FGFs, and methods of using such modified FGFs to treat ocular diseases, disorders, or conditions.
Abstract: Viral VEGF and viral anti-inflammatory cytokine compositions, methods of treatment using them, and kits containing them for use in the promotion and/or improvement of wound healing and/or tissue repair, and for anti-scarring, anti-inflammatory, anti-fibrosis and anti-adhesion indications.
Type:
Application
Filed:
March 16, 2016
Publication date:
September 15, 2016
Applicant:
OTAGO INNOVATION LIMITED
Inventors:
Lyn Marie WISE, Stephen Bruce Fleming, Andrew Allan MERCER
Abstract: The present invention relates to a method for detecting heart damage in a patient. The invention also relates to methods for treatment of patients identified as having heart damage. The invention further pertains to methods for evaluating the efficacy of an ongoing therapeutic regimen designated to treat a damaged heart in a patient.
Abstract: The invention relates to a method for preparing serums, said serums comprising cytokines and coagulation factors, and for preparing fibrin gel compositions, wherein the method comprises submitting an isolated biological sample comprising platelets and/or leukocytes to different steps of different gravity force to obtain supernatants with high concentrations of cytokines and coagulation factors. The invention also encompasses serums obtainable by this method, and other derived products comprising them. Uses of the products are disclosed, in particular its use as tissue regeneration.
Abstract: Embodiments are directed to compositions and methods of treating migraine and related neurological disorders. In certain aspects, methods and compositions are for reducing cortical spreading depression and/or suppressing the neurochemical basis for chronic and acute migraine events, and provide methods and pharmaceutical compositions related to both acute and preventive therapies for migraine events and related headaches.
Type:
Application
Filed:
June 2, 2016
Publication date:
September 15, 2016
Inventors:
Richard Kraig, Aya Pusic, Heidi Mitchell, Yelena Grinberg, Marcia Kraig
Abstract: The effects of hepcidin treatment on mitigating IRI and acute kidney injury by decreasing iron availability and ROS-mediated cell death were tested. C57Bl/6 (WT) and hepcidin knock out (Hamp?/?) mice were treated with saline or 50 ?g of hepcidin i.p. prior to bilateral renal IRI. Renal function, injury markers, histopathology, and inflammation were examined after 24 hours of reperfusion. In WT mice, IRI induced increases in serum and kidney non-heme iron levels, but hepcidin treatment induced sequestration of iron in the spleen and liver and prevented IRI-associated increases in serum and kidney non-heme iron. Kidney function was significantly better in hepcidin-treated mice, accompanied by less acute tubular necrosis and reduced infiltration of immune cells. Hepcidin treatment decreased kidney ferroportin expression and induced the expression of cytoprotectant, H-Ferritin, and was associated with less ROS and tubular epithelial apoptosis.
Abstract: The invention relates to PYY compounds having the amino acid in the position corresponding to position 35 of hPYY(1-36) substituted with beta-homoarginine and derivatives thereof with a modifying group attached to the position corresponding to position 7 of hPYY(1-36). The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.